KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Veterinary and Animal Sciences / 2005 / Cilt: 29 - Sayı: 2

In Vitro Efficacy of Azithromycin and Roxithromycin Against Toxoplasma gondii

Mehmet TANYÜKSEL
Sayfa
525–529
Yayın Tarihi
2005-02-01
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In conclusion, this observation should be assessed carefully in future clinical trials involving a large number of cases with toxoplasmosis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Toxoplasmosis is a common problem, accounting for significant morbidity in developing countries.
📊
Temel Bulgular & Veri:Better-tolerated and more effective drugs are clearly needed.
💡
Sonuç & Katkı:In conclusion, this observation should be assessed carefully in future clinical trials involving a large number of cases with toxoplasmosis.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Toxoplasma gondii · azithromycin · roxithromycin

Özet

Toxoplasmosis is a common problem, accounting for significant morbidity in developing countries. Conventional treatments are associated with frequent relapses and with additional problems including undesirable side effects. Better-tolerated and more effective drugs are clearly needed. The aim of this study is to evaluate the in vitro efficacy of azithromycin and roxithromycin against Toxoplasma gondii using acridine orange in the fluorescence microscopic assay. It was found that azithromycin and roxithromycin had significant microbicidal activity (P < 0.05). In conclusion, this observation should be assessed carefully in future clinical trials involving a large number of cases with toxoplasmosis.

Abstract

Toxoplasmosis is a common problem, accounting for significant morbidity in developing countries. Conventional treatments are associated with frequent relapses and with additional problems including undesirable side effects. Better-tolerated and more effective drugs are clearly needed. The aim of this study is to evaluate the in vitro efficacy of azithromycin and roxithromycin against Toxoplasma gondii using acridine orange in the fluorescence microscopic assay. It was found that azithromycin and roxithromycin had significant microbicidal activity (P < 0.05). In conclusion, this observation should be assessed carefully in future clinical trials involving a large number of cases with toxoplasmosis.

🔖

Bu Makaleye Atıf Yap

TANYÜKSEL, M. (2005). In Vitro Efficacy of Azithromycin and Roxithromycin Against Toxoplasma gondii. Turkish Journal of Veterinary and Animal Sciences, Cilt: 29 - Sayı: 2, 525–529. https://ajindex.com/articles/122375

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Georgiev, V.S.: Management of toxoplasmosis. Drugs 1994; 48:179-188. 2. Vannuffel, P., Cocito, C.: Mechanism of action of streptogramins and macrolids. Drugs, 1996; 51 (Suppl. 1): 20-30. 3. Khan, A.A., Slifer, T.R., Araujo, F.G., Remington, J.S.: Quinupristin-Dalfopristin is active against Toxoplasma gondii. Hoepelman, I.M., Scheneider, M.M.E.: Azithromycin: the first of the tissue-selective azalides. Int. J. Antimicrob. Agents, 1995; 5: 145-167.
  2. Jaruratanasirikul, S., Hortiwakul, R., Tantisarasart, T., Phuenpathom, N., Tussanasunthornwong, S.: Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob. Agents Chemother., 1996; 40: 825-826.
  3. Fichera, M.E., Mahendra, K.B., Roos, D.S.: In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob. Agents Chemother., 1995; 39: 1530-1537.
  4. Rothova, A., Bosch-Driessen, L.E., van Loon, N.H., Treffers, W.F.: Azithromycin for ocular toxoplasmosis. Br. J. Ophthalmol., 1998; 82: 1306-1308.
  5. Brun-Pascaud, M., Rajagopalan-Levasseur, P., Chau, F., Bertrand, G., Garry, L., Derouin, F., Girard, P.M.: Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model. Antimicrob. Agents Chemother., 1998; 42: 1068-1072.
  6. Romand, S., Bryskier, A., Moutot, M., Derouin, F.: In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii. J. Antimicrob. Chemother., 1995; 35: 821-832.
  7. Beckers, C.J.M., Roos, D.S., Donald, R.G.K., Luft, B.J., Schwab, J.C., Cao,Y., Joiner, K.A.: Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics. J. Clin. Invest., 1995; 95: 367- 376. Tripodi, M.F., Adinolfi, L.E., Utili, R., Marrone, A., Ruggiero, G.: Influence of subinhibitory concentrations of Loracarbef (LY 163892) and Laptomycin (LY 146032) on bacterial phagocytosis, killing and serum sensitivity. J. Antimicrobiol. Chem., 1990; 26: 491-501.
  8. Derouin, F.: New pathogens and mode of action of azithromycin: Toxoplasma gondii. Pathol. Biol. Paris, 1995; 43: 561-564.